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SUMMARY
Aim: This study aims to compare younger and older populations of lithium-treated patients and to examine the impact of long-
term lithium treatment on renal function.
Methods: A retrospective, cross-sectional survey of all patients attending a specialist clinic was carried out. Demographic, 
clinical and biochemical data from the two groups were compared, and stepwise regression was used to investigate an association 
between duration of lithium treatment and renal function.
Results: The findings reveal a positive association between duration of lithium use and mean serum creatinine levels (t=3.369, 
p=0.001), and so prolonged lithium treatment may be a risk factor for progressive renal impairment. However, under appropriate 
supervision this may not be of clinical relevance.
Conclusion: We conclude that lithium can be safely prescribed over a protracted period of time, even in elderly populations, but 
should be monitored closely under specialist supervision, to ensure early identification and management of adverse effects. 
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INTRODUCTION
Lithium  represents  one  of  the  triumphs  of  modern 
psychopharmacology.  Since  its  introduction  into  the  field 
of psychiatry, more than half a century ago, it has become 
established as a valuable and effective agent in the treatment 
of acute mania and in the prophylaxis of bipolar and unipolar 
affective  disorders1,2.  Its  use  in  other  conditions,  such  as 
augmentation  in  treatment  resistant  depression,  has  also 
been advocated3. In general it is considered as a long-term 
treatment strategy and therefore patients are often prescribed 
lithium over a period of many years.
Unfortunately  the  potential  side  effects  of  lithium  have 
always been an issue, and among these the possible impact 
of long-term lithium treatment on renal function has given 
rise to considerable concern4. Lithium is known to affect 
renal concentrating ability, and lithium-induced polyuria is 
not uncommon, estimated to affect approximately 20% of 
patients, but this is rarely clinically significant5. It is less clear, 
however, whether or not the protracted use of lithium can 
cause progressive deterioration in renal function, culminating 
in renal failure. Results of several long-term studies suggest 
that  this  is  not  the  case,  and  the  consensus  of  literature 
has been that in the absence of lithium toxicity, long-term 
sequelae are rare6,7. On the other hand there are a number of 
case reports which describe instances of renal insufficiency 
in lithium treated patients with no other obvious cause8,9. At 
the present time regular monitoring of renal function is still 
recommended.
Psychiatric clinics now treat cohorts of patients who have 
had protracted exposure to lithium, many of whom are of 
advancing age. The use of lithium in older people has the 
potential to be even more problematic for a number of reasons. 
Firstly, normal age-related reductions in renal clearance and 
volume of distribution can result in higher plasma levels 
of lithium and increase susceptibility to lithium toxicity. In 
addition, elderly patients are more likely to have co-morbid 
physical  health  problems,  and  to  be  taking  concomitant 
medications  that  may  have  significant  interactions  with 
lithium10.  The  prescription  of  ACE  inhibitors  and  loop 
diuretics  in  particular,  have  been  shown  to  dramatically 
increase the risk of lithium toxicity11.
In recent years there have been significant advances in a 
number of effective new treatments for affective disorders, 
which appear to have little impact on renal function and may 
offer an alternative to lithium12. Therefore it would seem 
prudent at this time to review the effects of lithium in clinic 
populations. The aim of this study is carry out a comparison 
of younger and older lithium-treated patients and to examine 
the association between duration of lithium treatment and 
renal function.
METHODS
All patients under review at a specialist out-patient clinic were © The Ulster Medical Society, 2008.
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considered for inclusion in the study. This clinic serves part of 
the population of South Belfast (estimated 75,000) and aims 
to provide regular monitoring of those patients who are treated 
with lithium or other mood-stabilizing drugs. 
In the first instance all patients currently prescribed lithium 
were identified. They were then interviewed to update history 
and information on demographic details and medical status. 
Following  this,  thorough  review  of  the  psychiatric  case 
notes was undertaken. Data collected included information 
on  patient’s  age,  psychiatric  (ICD-10)  diagnosis,  current 
medications, physical illnesses, duration of lithium treatment 
and episodes of lithium toxicity. In addition, the ten most 
recent serum lithium levels, urea and creatinine levels, and 
free thyroxine (T4) and thyroid-stimulating hormone (TSH) 
levels were recorded where possible, and average values of 
these figures were calculated. The mean of the last ten serum 
creatinine  levels  was  used  as  an 
estimate of renal function.
For  comparative  purposes  patients 
were  subdivided  into  two  groups 
- those under the age of 65yrs and 
those aged 65yrs and over. To allow 
comparison  between  the  groups 
the  Mann-Whitney  U  test  with 
Bonferroni  correction  was  used 
(statistical significance set at p<0.01). 
The  data  were  further  subject  to 
statistical analysis using a stepwise 
regression  model  to  investigate 
the  association  between  duration 
of  lithium  use  and  renal  function. 
Other  possible  predictors  of  renal 
function were entered into the model, 
including age, hypertension, diabetes, 
concomitant medications such as non-
steroidal  anti-inflammatory  drugs 
(NSAIDs) and diuretics, mean serum 
lithium level and episodes of lithium 
toxicity.
RESULTS
Fifty-nine  patients  currently 
prescribed lithium were identified.
Comparison of younger and older 
age  groups  of  lithium-treated 
patients
(i) Demographics
Thirty-eight patients were under the 
age of 65yrs, and twenty-one were 
aged 65yrs and over. The mean age of 
patients in the younger age group was 
45.5yrs and in the older group was 
72.8yrs.  Both  groups  had  a  higher 
proportion of female patients. Results 
of  demographic  details  for  both 
groups are displayed in Table I. 
(ii)  Clinical 
Ta b l e  I: 
Comparison of demographic information between younger 
and older age groups
Under 65yrs 
(n=38)




45.5 +/- 10.6 72.8 +/- 6.8
Age range 
(years)
19 – 63 65 - 88
Sex  M / F 15 / 23 7 / 14
Ta b l e  II:






     Bipolar affective disorder
     Recurrent  depressive disorder







Duration of lithium treatment (years) *
(mean +/- SD)
6.9 +/- 5.4 14.2 +/- 6.3
Range of duration of lithium treatment (years) 1 - 20 1 - 26
Average lithium dosage over past year **
(mg/day)
790.8 528.6
Episodes of lithium toxicity 0 0
Concomitant psychotropic medication (%)
     Carbamazepine
     Depakote
     Typical antipsychotic
     Atypical antipsychotic
     Selective serotonin reuptake inhibitor
     Serotonin/noradrenaline reuptake inhibitor















Concomitant physical medication (%)
     Thyroxine
     Other potentially nephrotoxic drugs 






     Hypertension





          *   Mann Whitney Z = -3.76, p = 0.0001
          ** Mann Whitney Z = -4.02, p = 0.001© The Ulster Medical Society, 2008.
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Table II represents the clinical characteristics of both groups 
with regards to psychiatric diagnosis and drug treatment. 
It is noted that in the younger age group the vast majority 
of patients are prescribed lithium for a diagnosis of bipolar 
affective disorder (84.2%), whereas in the older group the 
trend is rather different, with recurrent depressive disorder 
(47.6%) diagnosed in almost half of these patients.    
There  is  a  statistically  significant  difference  in  the  mean 
duration of lithium use between both groups; those in the 
younger age group have a mean duration of treatment of 6.9 
years, whereas the mean duration in the older age group is 14.2 
years (Z = -3.76, p = 0.0001 Mann-Whitney test). The average 
dose of lithium is also lower in the older age group (Z = -4.02, 
p = 0.0001). No patient in either group had had an episode 
of lithium toxicity. With regards to concomitant psychotropic 
medication, results suggest that those in the older age group 
are more likely to be prescribed older agents, such as typical 
antipsychotics and tricyclic antidepressants. This group are 
also more likely to require treatment with thyroxine, and to 
be prescribed other potentially nephrotoxic drugs. It is noted 
that the prevalence of thyroxine treatment in both groups far 
exceeds the community prevalence of hypothyroidism and 
possible explanations for this are discussed later.
(iii) Biochemistry
A comparison of results of biochemistry monitoring between 
the  two  groups  is  presented  in  Table  III.  There  are  no 
significant differences in serum lithium levels, free T4 levels 
or TSH levels between both groups. The urea level is slightly 
higher in the older group. The creatinine level in the older 
age group is also higher than in the younger group, but this 
difference does not reach statistical significance. 
Relationship between duration of lithium use and renal 
function
The best-fit model with stepwise regression accounted for 
24% of the variance (R2 = 0.238, p = 0.0001). Stepwise 
regression analysis revealed that only two individual predictors 
were significantly associated with serum creatinine level. The 
duration  of  lithium  treatment  was  found  to  be  positively 
correlated with mean serum creatinine level (t = 3.369, p = 
0.001). An association between serum creatinine level and a 
history of hypertension was also noted, although interestingly 
this was a negative correlation (t = -2.608, p = 0.012).
DISCUSSION
To the best of our knowledge this has been the largest study 
of its nature in the UK. It benefits from inclusion of a mixed 
age population and demonstrates what is happening in actual 
clinical practice. Importantly, it attempts to reflect differences 
in the use of lithium in younger and older populations, and to 
address particular concerns about the prescription of lithium 
over a prolonged period of time, often in patients of advanced 
age.
Any retrospective cross-sectional study of this nature will 
inevitably be limited by inherent methodological weaknesses. 
We acknowledge that this study may not capture all those 
prescribed  lithium  within  the  catchment  area,  but  we  are 
confident that the vast majority will have been included. It 
is also possible that this sample may not be representative 
of  lithium-treated  patients  in  other  areas,  but  again  our 
experience would suggest that similar practices exist across 
other parts of Northern Ireland. The relatively small sample 
size has potential to increase the likelihood of error and with 
a  larger  dataset  further  statistically  significant  differences 
between  the  groups  may  have  become  apparent.  One 
particular drawback in the design of this study is that it does 
not identify those people who may have already developed 
renal  impairment  and  had  lithium  treatment  withdrawn. 
However,  our  findings  would  indicate  that  even  if  this  is 
the case, close monitoring has led to identification of such 
patients and appropriate action taken. It is encouraging to 
note that indeed only one patient in the entire 
sample was found to have an average serum 
creatinine level in excess 130 µmol/l. 
Despite  the  potential  limitations  of  this 
study we feel that the findings are of value. 
Results of the comparative study indicate that 
although  there  is  a  statistically  significant 
difference  in  urea  level,  the  difference 
in  creatinine  levels  is  not  statistically 
significant.  Particularly  of  note,  there  are 
no  clinically  relevant  differences  between 
the two groups on any of the biochemical 
markers. Regression analysis does show that 
longer duration of lithium use is associated 
with higher creatinine levels, independent of 
age and other confounding factors. However, 
given the findings of the comparative study, 
this  is  not  necessarily  associated  with 
clinically  relevant  abnormalities  in  renal 
function.  Therefore,  although  progressive 
renal impairment should be considered a risk, 
this may not be of major clinical significance. 
The  importance  of  monitoring  glomerular 
filtration  rate  in  patients  receiving  long-
term  lithium  therapy  is  now  increasingly 
Ta b l e  III: 





 Serum lithium level (mmol/l) *
(mean +/- SD)
0.64 +/- 0.12 0.68 +/- 0.14
Free T4 levels (pmol/l)
(mean +/- SD)
12.6 +/- 1.98 12.9 +/- 1.45
TSH levels (mu/l)
(mean +/- SD)
2.53 +/- 1.87 3.20 +/- 3.05
Urea (mmol/l) **
(mean +/- SD)
4.31 +/- 0.96 5.72 +/- 1.46
Creatinine (µmol/l) ***
(mean +/- SD)
80.24 +/- 10.59 95.15 +/- 37.60
* Mann Whitney Z = -1.60, p = 0.10
** Mann Whitney Z = -3.95, p = 0.0001
*** Mann Whitney Z = -2.04, p = 0.04© The Ulster Medical Society, 2008.
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emphasised, and future studies should aim to use this as a 
marker of renal function13.
Several  other  findings  from  the  study  are  also  worth 
highlighting. It is interesting to note that much of the use 
of lithium in the elderly population is aimed at treatment of 
depressive illness, in contrast with the younger population 
where it is most frequently used in bipolar disorder. This is 
particularly  relevant  as  alternative  treatment  options  may 
be more limited in these cases. The high level of thyroxine 
prescribing  has  already  been  noted  but  we  feel  that  this 
is  in  keeping  with  other  studies  in  similar  poulations14. 
Hypothyroidism is a well-recognised side-effect of lithium, 
and in addition the use of thyroxine in treatment of subclinical 
hypothyroidism can sometimes be of value in management 
of  affective  disorders.  These  factors  almost  certainly 
account for the differences observed. There is also a rather 
unexpected finding of a negative correlation between serum 
creatinine level and history of hypertension. This is clearly 
counterintuitive.  However  closer  inspection  of  the  data 
reveals that only three patients in the study had a history of 
hypertension, and it is unlikely that results from such a small 
sample would be meaningful.
The results of this study are in keeping with other research 
which concludes that, in the vast majority of patients, lithium 
does  not  contribute  to  progressive  renal  impairment15. 
Although  lithium  may  adversely  affect  several  aspects  of 
renal function, it can be used safely over many years provided 
episodes of acute intoxication are avoided and renal function 
is carefully monitored. This view has been expressed by others 
who have studied the use of lithium in older patients16,17. 
However, if a serial decline in glomerular filtration rate is 
identified, that is more rapid than age-related decrease in 
renal function, then alternatives to lithium treatment should 
be considered.
In recent years there has been progress in our understanding of 
affective disorders and their management. Various alternatives 
to lithium prophylactic treatment have been advocated. These 
drugs may have different tolerability and safety profiles, and 
certainly are a welcome development given the potential side 
effects of lithium.
Unfortunately however their efficacy in long-term prophylaxis 
over years is not conclusive. As yet no other proposed mood-
stabilizing treatment has such substantial research evidence 
of long-term efficacy in bipolar disorder, as well as yielding a 
significant reduction in mortality risk from suicide18. It is also 
worth noting that most evidence to date relates to the general 
adult population, with limited research into their use in the 
elderly19. Therefore we would caution against an unnecessary 
trend to use modern alternatives until this is backed up by 
firm evidence. While we continue to await evidence of more 
effective and safer treatment, lithium should not be abandoned 
or feared.
The authors have no conflict of interest.
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